Email ID
Password
Scrip   
US panel backs Pfizer's Selzentry in treatment-naïve HIV
09 October 2009
Sue Sutter

A US FDA advisory panel has endorsed adding an HIV treatment-naïve indication to Pfizer's CCR5 antagonist Selzentry (maraviroc). In a 10 to four vote, the antiviral drugs advisory committee said safety, efficacy and resistance data support approval for combination treatment in HIV-1...



Please Login to read the full article.
JOB OF THE WEEK Promote your vacancy here
© 2010 Informa plc. All rights reserved.
This site is owned and operated by Informa plc ("Informa") whose registered office is Mortimer House, 37-41 Mortimer Street, London, W1T 3JH. Registered in England and Wales. Number 3099067. UK VAT Group: GB 365 4626 36